Summary.-Two cell lines, one sensitive and one resistant to the cytotoxic effects of cytosine arabinoside (AraC) were studied in vitro as a drug-resistance model. 
1-:-D ARABINOFURANOSYL CYTOSINE (AraC) is one of the most active drugs used in the treatment of acute leukaemias (Tattersall, 1977) . Its major biochemical effects have been ascribed to the competitive inhibition of DNA polymerase by the triphosphate derivative (AraCTP; Chou et al., 1975) . Resistance of tumour cells to the action of AraC frequently arises in patients with leukaemia (Tattersall et al., 1974) and is believed to be due to a decrease in the cellular phosphorylation of AraC to form AraCTP, and/or possibly increased AraC and arabinofuranosyl cytosine mnonophosphate (AraCMP) deamination to the inactive arabinofuranosyluridine (AraU) and arabinofuranosyluridine monophosphate (AraUMP) respectively, both leading to a reduction in the level of AraCTP produced (Tattersall et al., 1974; Coleman et al., 1975) . It is theoretically possible to overcome this type of resistance to AraC by introducing the active metabolite AraCTP directly into resistant cells, e.g. by using liposomes as carriers.
Liposomes (phospholipid vesicles) were originally used as model membrane systems (Bangham et al., 1965) but have recently been used to entrap a wide variety of compounds of therapeutic interest, several reviews of which have been published (Kimelberg & Mayhew, 1978; Gregoriadis, 1979; Ryman & Tyrrell, 1979) . There have also been several reports on the use of liposomes as carriers of anti-cancer agents, reviewed by Kaye & Richardson (1979) .
The use of liposomally trapped AraC against several animal tumours has been investigated (Mayhew et al., 1976; Rustum et al., 1979 , Ganapathi et al., 1980 (HBS) and i.p. injection of 0.1 ml of the cell suspension.
For in vitro study, the resistant cell line was harvested and washed twice with HBS. Erythrocytes were removed by flash lysis, by resuspending the cell pellet in 5 ml of distilled water followed 30 sec later by adding 5 ml of double-strength saline. Cells were then centrifuged and resuspended in HBS, counted and diluted to 2 x 106 cells/ml in HBS. The sensitive cell line was harvested by centrifugation from culture medium and was also washed and diluted to 2 x 106 cells/ml in HBS.
Preparation of liposomes.-Liposomes were prepared from various combinations of phosphatidylcholine (egg lecithin, PC) prepared by the method of Dawson (1958) , cholesterol (C, Sigma), phosphatidic acid (PA, Lipid Products), stearylamine (SA) and dicetylphosphate (DCP, K & K Labs, New York.
Five mg of lipid in chloroform were rotaryevaporated at 37°C under vacuum to form a dry lipid film. To this film was added 2-5 ml of Dulbecco's PBS, either alone or containing AraC or AraCTP at various concentrations, but both containing trace amounts of their tritiated components. Each batch of liposomes was then sonicated, using an exponential titanium probe, for 4 x 15 sec with cooling between in an ice bath. A 120W sonicator was used at an energy setting of 6-8 ,um peak-topeak. Trapped drug levels were then determined by passage through a Sephadex G50 column at 4°C. Most of the studies made were with liposomes composed of PC:C:PA in a 7:2: 1 molar ratio: entrapment of AraCTP in these was 0.4% of the total added. Liposomes used for in vitro studies were sterilized by passage through a 0 45,um sterile filter and were kept on ice until used later that day.
[3H]-dT-incorporation assay and lipid sen8itivity.-A method similar to that of Curt et al. (1976) was used. Several different lipid compositions were used in this study to determine their effects on [3H]-dT incorporation into cellular DNA. 106 cells in 0 5 ml of HBS were added in triplicate to 0 5 ml of liposome suspension in Dulbecco's PBS. The cells were then incubated with shaking in an atmosphere of 5% CO2 and air for various intervals at 37°C, followed by addition of 1 ,uCi [3H]-dT (46 Ci/mmol) and 30 min later 0 5 ml of 1 OmM ice-cold dT was added and the tubes put into ice. Cells were then filtered on to Whatman GFC filters and washed x 3 with 5% trichloroacetic acid and twice with ethanol, and then allowed to dry at 37°C.
[3H]-dT incorporation was then determined by scintillation counting. All results of labelled dT incorporation were expressed as a percentage of the controls not exposed to lipid. Cell clumping and pH changes were minimized by gently shaking in the 5% CO2 atmosphere. Viability of control groups at the end of the incubation was never below 90%. the AraC-resistant cell line to liposomally trapped AraC and AraCTP as well as free AraCTP and a mixture of free AraCTP with empty liposomes was tested using the [3H]-dT-incorporation assay described above. Liposomes composed of a 7:2:1 molar ratio of PC: C: PA were used. It is essential to point out here that all liposome preparations were used without separation from the free drug used in their preparation. This was to ensure more reproducible conditions and simplify the methodology. This also necessitated the use of the free drug plus empty liposome control. (Tyrrell et al., 1977; Layton et al., 1980; Campbell, 1980) and in vivo (Bruni et al., 1976; De Barsey et al., 1976; Adams et al., 1977; Steger & Desnick, 1977) . Liposome toxicity must be considered when making any measurements involving the use of liposomes. The 2 components believed to be responsible for the inhibition of dT incorporation into DNA in the assay system are stearylamine and dicetylphosphate. Liposomes containing phosphatidic acid as the charged component had little or no inhibitory effect on dT incorporation.
The ID50 for the effects of AraC on the drug-sensitive and drug-resistant cell lines differs by at least 3 logs (see Fig. 2) . A drug-resistant cell line offers a means of investigating the mechanism(s) of action of liposomally trapped drug, by eliminating the confusing side effects produced by free drug in the liposomal preparation, or the leakage of drug during incubation.
To date we are unable to say whether the resistant cell line used in these studies was resistant to AraC because of decreased deoxycytidine kinase levels, enhanced deoxycytidine deaminase and/or deoxycytidylate deaminase levels or to some other possible mechanism. We could be certain, however, that resistance to AraC was not due to a permeability defect. Not only would this be improbable (see Mulder & Harrap, 1975) , but our results with liposomally trapped AraC showed no greater inhibition of DNA synthesis than those with free AraC. Other workers have suggested that it is most probable that AraC resistance develops through changes in the level(s) of one or more of the three enzymes described above (Tattersall et al., 1974; Coleman et al., 1975) .
The sensitivity of the drug-resistant cell line to the liposomal form of AraCTP indicates that the liposomes are able to introduce their contents intracellularly in an active form capable of inhibiting DNA synthesis. However, there is a considerable difference between the ID50 for AraC in the drug-sensitive cell line (7 0 nM), and the ID50 for liposomally trapped AraCTP in the drug-resistant cell line (0-1-1-0 EM). This may be due to the low level of drug trapped in the liposomes (0.4%o) and possibly the low uptake of liposome by the cells.
The variations in liposomal AraCTP sensitivity found for the resistant cell line were most probably duie to variations in the batches of cells used. We had to grow the resistant cells in vivo and harvest the cells from ascitic fluid when required for experiment. These cells varied from week to week with respect to contaminating blood cells. The poorest results were obtained when there was the highest level of erythrocyte contamination, with cell preparation requiring 3 cycles of osmotic lysis for their removal. The 5f-63 best results were from batches of cells requiring only a single lysis to remove contaminating erythrocytes.
It appears from the data that liposomes are capable of acting as drug carriers, and that liposomal AraCTP is effective in overcoming the AraC-resistance of the TLX-5 resistant cell line in vitro. It now remains to test these cells in mice, to see whether it is still possible to overcome AraC resistance in this way.
